Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication

Masayuki Hashiguchi, Keiko Ohno, Ryoko Saito

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To study the effectiveness for the treatment of intermittent claudication (IC) of three drugs with antiplatelet effects, cilostazol, beraprost sodium, and prostaglandin E1 (PGE1), by using a systemic review of literature and a meta-analysis. A search was undertaken for studies reported between 1966-2002 in the MEDLINE database, and references in published articles and reviews were obtained. Data for maximum walking distance (MWD), pain-free walking distance (PFWD), and adverse clinical events were extracted from the articles that met the inclusion criteria. The pooled estimates of the weighted mean differences (WMD) of MWD and PFWD for cilostazol were 52.19 m [95% confidence interval (CI) 32.08, 72.31] and 39.75 m [95% CI 23.39, 56.10], and those for PGE1 were 100.27 m [95% CI 15.76, 184.78] and 55.73 [95% CI 21.54, 89.92], respectively. These differences were statistically significant between the test drugs and placebo. However there was no statistical significance difference between beraprost sodium and placebo, even though there was one study that showed a tendency for improvement in walking distance. The total rate of adverse clinical events in cilostazol and beraprost sodium was higher than that for placebo, while there was no statistical significant difference between PGE1 and placebo, although PGE1 had a higher tendency for adverse clinical events. The literature evaluation results and the meta-analysis suggest that these two drugs (cilostazol and PGE 1) can be considered to be effective drugs for the treatment of IC. Due to current availability of only a few clinical reports, further studies are needed to clarify the efficacy of beraprost sodium in the treatment of IC.

Original languageEnglish
Pages (from-to)321-332
Number of pages12
JournalYakugaku Zasshi
Volume124
Issue number6
DOIs
Publication statusPublished - 2004 Jun
Externally publishedYes

Fingerprint

beraprost
Intermittent Claudication
Alprostadil
Walking
Safety
Placebos
Confidence Intervals
Meta-Analysis
Pharmaceutical Preparations
Therapeutics
Platelet Aggregation Inhibitors
Prostaglandins E
MEDLINE
cilostazol
Databases

Keywords

  • Cilostazol
  • Effectiveness
  • Intermittent claudication
  • Meta-analysis
  • Prostaglandins
  • Safety

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. / Hashiguchi, Masayuki; Ohno, Keiko; Saito, Ryoko.

In: Yakugaku Zasshi, Vol. 124, No. 6, 06.2004, p. 321-332.

Research output: Contribution to journalArticle

@article{bdf7fb27c33b4215a0cd5e368467a9a9,
title = "Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication",
abstract = "To study the effectiveness for the treatment of intermittent claudication (IC) of three drugs with antiplatelet effects, cilostazol, beraprost sodium, and prostaglandin E1 (PGE1), by using a systemic review of literature and a meta-analysis. A search was undertaken for studies reported between 1966-2002 in the MEDLINE database, and references in published articles and reviews were obtained. Data for maximum walking distance (MWD), pain-free walking distance (PFWD), and adverse clinical events were extracted from the articles that met the inclusion criteria. The pooled estimates of the weighted mean differences (WMD) of MWD and PFWD for cilostazol were 52.19 m [95{\%} confidence interval (CI) 32.08, 72.31] and 39.75 m [95{\%} CI 23.39, 56.10], and those for PGE1 were 100.27 m [95{\%} CI 15.76, 184.78] and 55.73 [95{\%} CI 21.54, 89.92], respectively. These differences were statistically significant between the test drugs and placebo. However there was no statistical significance difference between beraprost sodium and placebo, even though there was one study that showed a tendency for improvement in walking distance. The total rate of adverse clinical events in cilostazol and beraprost sodium was higher than that for placebo, while there was no statistical significant difference between PGE1 and placebo, although PGE1 had a higher tendency for adverse clinical events. The literature evaluation results and the meta-analysis suggest that these two drugs (cilostazol and PGE 1) can be considered to be effective drugs for the treatment of IC. Due to current availability of only a few clinical reports, further studies are needed to clarify the efficacy of beraprost sodium in the treatment of IC.",
keywords = "Cilostazol, Effectiveness, Intermittent claudication, Meta-analysis, Prostaglandins, Safety",
author = "Masayuki Hashiguchi and Keiko Ohno and Ryoko Saito",
year = "2004",
month = "6",
doi = "10.1248/yakushi.124.321",
language = "English",
volume = "124",
pages = "321--332",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication

AU - Hashiguchi, Masayuki

AU - Ohno, Keiko

AU - Saito, Ryoko

PY - 2004/6

Y1 - 2004/6

N2 - To study the effectiveness for the treatment of intermittent claudication (IC) of three drugs with antiplatelet effects, cilostazol, beraprost sodium, and prostaglandin E1 (PGE1), by using a systemic review of literature and a meta-analysis. A search was undertaken for studies reported between 1966-2002 in the MEDLINE database, and references in published articles and reviews were obtained. Data for maximum walking distance (MWD), pain-free walking distance (PFWD), and adverse clinical events were extracted from the articles that met the inclusion criteria. The pooled estimates of the weighted mean differences (WMD) of MWD and PFWD for cilostazol were 52.19 m [95% confidence interval (CI) 32.08, 72.31] and 39.75 m [95% CI 23.39, 56.10], and those for PGE1 were 100.27 m [95% CI 15.76, 184.78] and 55.73 [95% CI 21.54, 89.92], respectively. These differences were statistically significant between the test drugs and placebo. However there was no statistical significance difference between beraprost sodium and placebo, even though there was one study that showed a tendency for improvement in walking distance. The total rate of adverse clinical events in cilostazol and beraprost sodium was higher than that for placebo, while there was no statistical significant difference between PGE1 and placebo, although PGE1 had a higher tendency for adverse clinical events. The literature evaluation results and the meta-analysis suggest that these two drugs (cilostazol and PGE 1) can be considered to be effective drugs for the treatment of IC. Due to current availability of only a few clinical reports, further studies are needed to clarify the efficacy of beraprost sodium in the treatment of IC.

AB - To study the effectiveness for the treatment of intermittent claudication (IC) of three drugs with antiplatelet effects, cilostazol, beraprost sodium, and prostaglandin E1 (PGE1), by using a systemic review of literature and a meta-analysis. A search was undertaken for studies reported between 1966-2002 in the MEDLINE database, and references in published articles and reviews were obtained. Data for maximum walking distance (MWD), pain-free walking distance (PFWD), and adverse clinical events were extracted from the articles that met the inclusion criteria. The pooled estimates of the weighted mean differences (WMD) of MWD and PFWD for cilostazol were 52.19 m [95% confidence interval (CI) 32.08, 72.31] and 39.75 m [95% CI 23.39, 56.10], and those for PGE1 were 100.27 m [95% CI 15.76, 184.78] and 55.73 [95% CI 21.54, 89.92], respectively. These differences were statistically significant between the test drugs and placebo. However there was no statistical significance difference between beraprost sodium and placebo, even though there was one study that showed a tendency for improvement in walking distance. The total rate of adverse clinical events in cilostazol and beraprost sodium was higher than that for placebo, while there was no statistical significant difference between PGE1 and placebo, although PGE1 had a higher tendency for adverse clinical events. The literature evaluation results and the meta-analysis suggest that these two drugs (cilostazol and PGE 1) can be considered to be effective drugs for the treatment of IC. Due to current availability of only a few clinical reports, further studies are needed to clarify the efficacy of beraprost sodium in the treatment of IC.

KW - Cilostazol

KW - Effectiveness

KW - Intermittent claudication

KW - Meta-analysis

KW - Prostaglandins

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=4143136625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143136625&partnerID=8YFLogxK

U2 - 10.1248/yakushi.124.321

DO - 10.1248/yakushi.124.321

M3 - Article

C2 - 15170067

AN - SCOPUS:4143136625

VL - 124

SP - 321

EP - 332

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 6

ER -